TNF and Cowden disease: CALM demonstrated a clear benefit, in terms of clinical and endoscopic outcomes, of escalating anti-TNFα and thiopurine therapy at early stages of CD on the basis of measures of disease activity defined by clinical symptoms and biomarkers.